FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Published at www.nejm.org June 6, 2008 (10.1056/NEJMe0803831)

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by The Action to Control Cardiovascular Risk in Diabetes Study Group Related Article by The ADVANCE Collaborative Group PubMed Citation

Cardiovascular disease in patients with diabetes is clearly associated with the degree of hyperglycemia, as measured clinically with the use of glycated hemoglobin.^1,2,3 However, there remains an unanswered question in diabetes management: Does the targeting of near normal levels of glycated hemoglobin reduce the rate of cardiovascular events? Randomized clinical trials that address this question are ongoing.

In this issue of the Journal, results are presented from two recently completed multicenter clinical trials, the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial (ClinicalTrials.gov number, NCT00000620 [ClinicalTrials.gov] )⁴ and the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified . . . [Full Text of this Article]

Source Information

From the Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge.

This article (10.1056/NEJMe0803831) was published at www.nejm.org on June 6, 2008. It will appear in the June 12 issue of the Journal.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.